Macroglobulinemia Waldenstrom 2 C1864876
A related form of Waldenström macroglobulinemia, a rare blood cancer affecting certain white blood cells. It causes overproduction of abnormal proteins in the blood. Treatment depends on symptoms and may include immunotherapy.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hyperviscosity symptoms
Bleeding
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Peripheral neuropathy
(hematologic)Hepatosplenomegaly
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anti-CD20 monoclonal antibody therapy
Rituximab-based regimens targeting malignant B-cells expressing CD20 surface antigen. This immunotherapy is often combined with other agents for optimal response. Regular infusion schedule under specialist supervision required.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Plasmapheresis
Therapeutic plasma exchange to rapidly reduce serum IgM levels and address hyperviscosity symptoms. Typically used as bridge therapy while awaiting response to definitive treatment. Vascular access via central line required.
Additional treatment options
BTK inhibitor therapy
Targeted therapy using Bruton tyrosine kinase inhibitors to disrupt signaling pathways essential for B-cell survival and proliferation. Oral administration with regular monitoring of hematologic parameters.
medicationRegular disease surveillance
Serial serum IgM quantification and imaging studies to assess treatment response and detect disease progression. Bone marrow evaluation may be warranted periodically.
monitoringAutologous stem cell transplantation
High-dose chemotherapy followed by reinfusion of patient's own stem cells for eligible patients with relapsed or refractory disease. Requires specialized transplant center facility and expertise.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Macroglobulinemia Waldenstrom 2 C1864876?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Macroglobulinemia Waldenstrom 2 C1864876. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy